Search Videos and More

Showing 1 - 12 of 620 results

Previous| 1 | 2 | 3 ...52 |Next


Turning Promise Into Progress News

Turning Promise Into Progress

How new cancer treatments reach patients and help shape the next cycle of discovery
Dana-Farber Research News 11.01.2026 News

Dana-Farber Research News 11.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from October 1 - 15.
Dana-Farber Science Uncovers Differences Between Early-Onset and Average-Age-Onset Colorectal Cancer News

Dana-Farber Science Uncovers Differences Between Early-Onset and Average-Age-Onset Colorectal Cancer

Colorectal cancer is on the rise in younger adults and appears to be different from colorectal cancer in older adults. The disease is often more aggressive in young people, and less responsive to treatment.  
Treatment Guideline: First-Line Treatment of HER2-Positive Metastatic Breast Cancer Document

Treatment Guideline: First-Line Treatment of HER2-Positive Metastatic Breast Cancer

The Breast Oncology Center held meetings to discuss recommendations regarding first-line treatment of patients with HER2-positive metastatic breast cancer.
Immunotherapy Combo Extends Survival for Patients with Aggressive Small Cell Lung Cancer, Based on Trial Results Presented by Dana-Farber at ESMO Congress 2026 News

Immunotherapy Combo Extends Survival for Patients with Aggressive Small Cell Lung Cancer, Based on Trial Results Presented by Dana-Farber at ESMO Congress 2026

Results suggest that introducing tarlatamab, a bispecific T-cell engager, earlier in treatment could meaningfully extend survival for a broader group of patients
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Substudy Supports Reduced Risk of Metastasis and Death News

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Substudy Supports Reduced Risk of Metastasis and Death

New analysis provides additional evidence on how the PROTEUS regimen compares with standard of care.
Dana-Farber presents phase 3 lung cancer data in ESMO presidential symposium News

Dana-Farber presents phase 3 lung cancer data in ESMO presidential symposium

Additional key study updates in prostate, breast and kidney cancer, and a special symposium focused on personalized cancer vaccines
Dana-Farber Breaks Ground on Lavine Bekenstein Cancer Hospital News

Dana-Farber Breaks Ground on Lavine Bekenstein Cancer Hospital

Historic ceremony marks the beginning of a new era in cancer care, led by Dana-Farber in collaboration with Beth Israel Deaconess Medical Center
Dana-Farber Research News 10.15.2026 News

Dana-Farber Research News 10.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 - 30.
ESMO Congress 2026 Symposium

ESMO Congress 2026

Preview news releases and presentations by Dana-Farber Physician-Scientists at this year's ESMO Congress 2026 in Madrid, Spain, October 23 - 27, 2026.
Dana-Farber Scientists Reveal How Follicular Lymphoma Transitions to More Aggressive Disease News

Dana-Farber Scientists Reveal How Follicular Lymphoma Transitions to More Aggressive Disease

Erin Parry, MD, PhD, cares for patients with follicular lymphoma, a form of blood cancer that affects immune cells called B cells in the lymph nodes. It is considered “indolent,” meaning it grows very slowly and often does not require treatment. In about 10 to 25 percent of patients, however, the disease transforms into an aggressive type of lymphoma that requires immediate intervention.
Novel Antibody-Drug Conjugate Demonstrates Durable Responses in Patients With Platinum-Resistant Ovarian Cancer News

Novel Antibody-Drug Conjugate Demonstrates Durable Responses in Patients With Platinum-Resistant Ovarian Cancer

An investigational antibody-drug conjugate demonstrated clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, including patients whose tumors had low or no expression of folate receptor alpha (FRalpha), according to findings from the Phase 1/2 RAINFOL-01 clinical trial.

Showing 1 - 12 of 620 results

Previous| 1 | 2 | 3 ...52 |Next